An intergroup phase III trial of Ramucirumab plus Irinotecan in third or more line Beyond progression after Ramucirumab for Advanced Gastric cancer.
Phase of Trial: Phase III
Latest Information Update: 03 Jul 2017
At a glance
- Drugs Ramucirumab (Primary) ; Irinotecan
- Indications Gastric cancer
- Focus Therapeutic Use
- Acronyms RINDBeRG trial
- 21 Feb 2017 Status changed from not yet recruiting to recruiting.
- 15 Jul 2016 New trial record